Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership

[1]  M. Loeb,et al.  The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Donnelly,et al.  Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults , 2021, The Lancet Regional Health - Europe.

[3]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[4]  Tonja M. Kyle,et al.  Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020 , 2020, JAMA internal medicine.

[5]  C. la Vecchia,et al.  Serological follow-up of SARS-CoV-2 asymptomatic subjects , 2020, Scientific Reports.

[6]  G. Screaton,et al.  The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers , 2020, medRxiv.

[7]  S. Ciesek,et al.  Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, The Journal of Infectious Diseases.

[8]  S. Ciesek,et al.  Analysis of humoral immune responses in SARS-CoV-2 infected patients , 2020, The Journal of infectious diseases.

[9]  C. Donnelly,et al.  Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults , 2020, medRxiv.

[10]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[11]  M. Leeflang,et al.  SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis , 2020, Clinical Microbiology and Infection.

[12]  M. Dake,et al.  Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity , 2020, Immunity.

[13]  B. Zhang,et al.  Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections , 2020, Allergy.

[14]  Matthew S. Miller,et al.  Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike , 2020, Cell Reports Medicine.

[15]  M. Loeb,et al.  Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Veldhoen,et al.  Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset , 2020, medRxiv.

[17]  Kathleen M. Akgün,et al.  Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study , 2020, PLoS medicine.

[18]  A. Casto,et al.  Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection , 2020, medRxiv.

[19]  C. John,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection in Children and Adults in Marion County, Indiana , 2020, Cureus.

[20]  Brian E. Dixon,et al.  Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[21]  Otto O. Yang,et al.  Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.

[22]  M. Poljak,et al.  Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample , 2020, Clinical Microbiology and Infection.

[23]  V. Martel-Laferrière,et al.  Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals , 2020, mBio.

[24]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[25]  Chul-Joong Kim,et al.  Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients , 2020, Journal of clinical medicine.

[26]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[27]  C. Reed,et al.  Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 , 2020, medRxiv.

[28]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[29]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[30]  Matthew S. Miller,et al.  Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike , 2020, bioRxiv.

[31]  Chunbao Xie,et al.  Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China , 2020, Nature Medicine.

[32]  Y. Pan,et al.  Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients , 2020, Clinical Infectious Diseases.

[33]  C. Rentsch,et al.  Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans , 2020, medRxiv.

[34]  Sang Woo Park,et al.  Modeling shield immunity to reduce COVID-19 epidemic spread , 2020, Nature Medicine.

[35]  Y. Xiong,et al.  Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China , 2020, JAMA network open.

[36]  Kari Stefansson,et al.  Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.

[37]  Xihong Lin,et al.  Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. , 2020, JAMA.

[38]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[39]  Clifford Anderson-Bergman,et al.  icenReg: Regression Models for Interval Censored Data in R , 2017 .

[40]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[41]  R B D'Agostino,et al.  Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. , 1992, Biometrics.

[42]  Wei Pan,et al.  Extending the Iterative Convex Minorant Algorithm to the Cox Model for Interval Censored Data , 2011 .